Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

14.57 2.39

Overview

Share price change

24h

Current

Min

13.86

Max

14.64

Key metrics

By Trading Economics

Income

-8.9M

-8M

Sales

3.7M

139M

P/E

Sector Avg

143.1

47.946

Profit margin

-5.724

Employees

1,790

EBITDA

18M

4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+17.63% upside

Market Stats

By TradingEconomics

Market Cap

575M

2.5B

Previous open

12.18

Previous close

14.57

News Sentiment

By Acuity

50%

50%

115 / 340 Healthcare

Hutchison China MediTech Ltd ADR Chart

Past performance is not a reliable indicator of future results.

Related News

6 Oct 2026, 23:45 UTC

News

Digital Realty Trust Inc closed CHF510 million in Swiss bonds and priced €1 billion in guaranteed notes, contributing to gains in after-market hours.

6 Oct 2026, 23:35 UTC

News
Event

BridgeBio Pharma plans to present new data on acoramidis and encaleret at upcoming scientific meetings, with shares roughly flat in after-market trading.

6 Oct 2026, 23:31 UTC

News

BHP Group Ltd is higher in after-market trading following its agreement to divest the Kambalda Nickel Concentrator to Gold Fields, pending regulatory approvals.

6 Oct 2026, 23:30 UTC

News

Regeneron Pharmaceuticals Inc. is trading modestly lower in after-market hours, continuing a downward trend and positioned near the lower end of its one-month range.

6 Oct 2026, 23:25 UTC

News

Cheniere Energy Inc. shares are higher in after-market trading following increased LNG shipments and a raised 2026 guidance amid ongoing LNG market disruptions.

6 Oct 2026, 23:11 UTC

News
Correlated Moves

USD/PLN is lower, continuing a decline since Monday, amid concerns from a widening U.S. trade deficit of $105.6 billion in August.

6 Oct 2026, 23:06 UTC

News
Correlated Moves

The USD/CZK is trading modestly lower, influenced by a strengthening euro and a widening U.S. trade deficit of $105.6 billion in August.

6 Oct 2026, 23:05 UTC

News

Hercules Capital secures a $150 million credit facility with Rocket Pharmaceuticals, including an initial $35 million disbursement, boosting shares in after-market hours.

6 Oct 2026, 23:05 UTC

News

Barclays initiated coverage on Boston Scientific Corp with an Equalweight rating and a price target of $48.00, as shares trade flat in after-market hours.

6 Oct 2026, 23:05 UTC

News

NextEra Energy Inc proposes a $15.5 million settlement in a derivative action, with shares trading higher in after-market hours following the announcement.

6 Oct 2026, 23:05 UTC

News

Procter & Gamble Co trades roughly flat since Tuesday's close.

6 Oct 2026, 23:01 UTC

News

JetBlue Airways' shares have advanced in after-market trading following the FAA's approval to transfer 22 slots at New York LaGuardia Airport from Spirit Airlines.

6 Oct 2026, 23:01 UTC

News
Social Media

NVIDIA shares have moved higher in after-market trading, supported by SpaceX's $40 billion financing effort to purchase NVIDIA chips for AI enhancements.

6 Oct 2026, 23:01 UTC

Social Media
News

Zeta Global Holdings Corp is acquiring Digital Audience to enhance its digital capabilities, with shares advancing in after-market trading following the announcement.

6 Oct 2026, 23:01 UTC

Social Media
News

Sigma Lithium Corporation has resumed mining operations in Brazil after a court upheld its environmental licenses, leading to a sharp rise in shares during after-market trading.

6 Oct 2026, 23:01 UTC

News
Social Media
Event

Constellation Brands reported Q2 adjusted EPS of $3.74, exceeding estimates, but maintained full-year guidance below consensus, leading to a significant after-market decline.

6 Oct 2026, 23:01 UTC

News
Social Media

ZIM Integrated Shipping Services raised its 2026 guidance, projecting Adjusted EBITDA of $2.7B to $3.0B, driving shares higher in after-market trading.

6 Oct 2026, 23:01 UTC

News

Shell PLC is monitoring its Gulf assets due to Invest 92L, while shares are advancing modestly in after-market trading, above their 20-day moving average.

6 Oct 2026, 23:01 UTC

Social Media
News

Constellation Energy Corp's stock declined in after-hours trading despite announcing a $4.3 billion agreement with Google to upgrade nuclear units and increase electricity capacity.

6 Oct 2026, 23:01 UTC

News
Social Media
Event

Neogen Corp reported Q1 revenue of $222.8 million, exceeding expectations, and raised FY 2027 revenue guidance, leading to a sharp rise in after-market hours trading.

6 Oct 2026, 23:01 UTC

News

Lucid Group Inc reported third-quarter deliveries of 3.81k units, falling short of estimates, leading to modest declines in after-market trading.

6 Oct 2026, 23:00 UTC

News

Black Hills Corp has entered agreements for a $1.8 billion Google data center project, boosting after-market trading significantly since Tuesday's close.

6 Oct 2026, 22:50 UTC

News
Social Media

Fair Isaac Corporation plans to cut 15% of its workforce, incurring $27 million in charges, as shares traded lower after-market.

6 Oct 2026, 22:50 UTC

News

Apollo Global Management is leading a $40 billion financing effort for SpaceX, with shares advancing modestly in after-market trading.

6 Oct 2026, 22:41 UTC

News

Revvity Inc shares declined in after-market trading despite an Outperform rating from William Blair, closing at their lowest point since Tuesday.

6 Oct 2026, 22:40 UTC

News

GE Healthcare Technologies Inc is trading higher in after-market hours following Barclays' initiation of coverage with an Overweight rating and a $85.00 price target.

6 Oct 2026, 22:30 UTC

News

ONEOK completed its $4.425 billion acquisition of Brazos Midstream's assets, more than doubling its Midland Basin processing capacity, boosting shares in after-market hours.

6 Oct 2026, 22:15 UTC

News

MetLife Inc announced a quarterly dividend of $0.5925 per share, with shares trading modestly higher in after-market hours following the announcement.

6 Oct 2026, 22:11 UTC

News

Simpson Manufacturing Co. shares are declining in after-market trading as its 2026 financial guidance remains unchanged amid a delayed land transaction closing.

6 Oct 2026, 22:06 UTC

News

Cirrus Logic announced the acquisition of INVENTVM Semiconductor to enhance engineering capacity, with shares trading slightly higher in after-market hours.

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

17.63% upside

12 Months Forecast

Average 16.833 USD  17.63%

High 18.5 USD

Low 14 USD

Based on 3 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Sentiment

By Acuity

115 / 340 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.